Poster: polyclonal solution for next generation multispecific antibody therapeutics

14 Dec 2021

The field of therapeutic antibody drugs has experienced explosive growth with now more than 120 molecules approved for treating various human diseases, including many cancers, autoimmune, metabolic and infectious diseases. Thanks to recombinant methods their development is still evolving creating a next generation that can take different shapes such as bispecific, trispecific, multispecific, ScFv (Singlechain variable Fragment) or ADC (Antibody-Drug Conjugate). In the context of these next generation antibodies therapeutics, the challenge echoes on preclinical and clinical immunoassay development to build antibody tools, like Anti-Drug Antibodies (ADA), Neutralizing ADA (NADA), antiidiotype (anti-ID), for bioanalysis methods such as immunogenicity (positive control) and Pharmacokinetics (PK).